GPP
HRTX icon

Great Point Partners’s Heron Therapeutics HRTX Stock Holding History

Great Point Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,737,368
Closed -$4.88M – 41
2023
Q3 		$4.88M Hold
4,737,368
– – 0.89% 32
2023
Q2 		$5.5M Sell
4,737,368
-1,080,000
-19% -$1.93M 1.08% 29
2023
Q1 		$8.78M Sell
5,817,368
-542,793
-9% -$1.36M 1.72% 23
2022
Q4 		$15.9M Buy
6,360,161
+715,000
+13% +$2.3M 3.12% 12
2022
Q3 		$23.5M Buy
+5,645,161
New +$22.1M 5.65% 6
2015
Q2 		– Sell
-270,000
Closed -$3.93M – 36
2015
Q1 		$3.93M Buy
+270,000
New +$3.04M 1.73% 18

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Great Point Partners's HRTX Position: Q4 2023 in Review

Great Point Partners sold out of Heron Therapeutics (HRTX) in Q4 2023, closing a stake of 4,737,368 shares — an estimated $4.88M sold.

Great Point Partners first reported a position in HRTX in Q1 2015 and held it in 6 quarters. The position peaked at $23.5M in Q3 2022. 151 funds tracked by Wall St. Rank hold HRTX as of Q4 2023.

  • Great Point Partners reported no remaining Heron Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 4,737,368 Heron Therapeutics shares in Q4 2023, an estimated $4.88M.
  • Great Point Partners first reported a position in Heron Therapeutics in Q1 2015 and held it in 6 quarters.
  • Great Point Partners's Heron Therapeutics position peaked at $23.5M in Q3 2022.
  • 151 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.